Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

theThroatSlasher Oct. 24 at 11:12 AM

$NEUP management is buying its own stock to prevent it from sliding off the damned edge into a precipice and joining goofs such as $GUTS back on Aug 6

0 · Reply

speculator Oct. 23 at 11:27 AM

$GUTS 683 Capital Management, LLC Increases Stake in Fractyl Health Inc https://www.gurufocus.com/news/3149119/683-capital-management-llc-increases-stake-in-fractyl-health-inc / https://www.sec.gov/Archives/edgar/data/1572616/000108514625005954/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

Mr_Pean Oct. 23 at 11:09 AM

$GUTS no need for maintenance GLP-1 shots for life! Revita addresses the root cause of obesity with a an outpatient procedure to provide durable weight maintenance for patients living with obesity!

0 · Reply

BioRich Oct. 23 at 3:08 AM

$ALT $GUTS I love it when my biggest stalker tries to bash me and my picks, only to fall on their face... yet again. Thanks for trying to get cute with $GUTS. You know, $GUTS that is the only clinical trial treatment to RETAIN weight loss following GLP-1 discontinuation. That one. In a turn of beautiful fortune, $GUTS proceeded to gain 4.7% from the time of your ill-advised bash attempt. Oh, and went down 2.5%. So that means your EE is 7.2% on your embarrassing post. *EE - Effective Embarrassment For those looking to make money and not just join bagholding misery cults... Follow/ Subscribe for more suggestions and perspective. Would love to hear yours. Let's make some money. Cheers!

0 · Reply

Fede_Tech Oct. 21 at 11:24 AM

$GUTS Current value: $1.39 MA200: $1.49 If it breaks, it will explode. Simple as that.

0 · Reply

Mr_Pean Oct. 21 at 5:56 AM

$GUTS my kind of day!

0 · Reply

Fede_Tech Oct. 20 at 9:33 PM

$GUTS 6,412,201 shares held by Peter Thiel, which looks like it has found bottom.

0 · Reply

tmpl Oct. 20 at 7:58 PM

$GUTS It is almost there

0 · Reply

BioRich Oct. 17 at 7:57 PM

$ALT Imagine if you bought $NUAI when I suggested it. Keeps running. You'd have made back your losses multiple times over. Watch $IDYA after hours, and make sure you get some more $GUTS on the gift day. $SBFM has been a nice winner this week as well. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. Let's make some money. Cheers!

1 · Reply

Mr_Pean Oct. 15 at 11:56 PM

$GUTS was hoping for more out of today.

2 · Reply

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Oct 1, 2025, 5:14 AM EDT - 24 days ago

Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang

Sep 26, 2025, 11:07 AM EDT - 4 weeks ago

Fractyl Health, Inc. - Special Call

Sep 26, 2025, 7:41 AM EDT - 4 weeks ago

Fractyl Health says experimental procedure helps maintain weight-loss in study

Sep 26, 2025, 7:05 AM EDT - 4 weeks ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sep 26, 2025, 7:00 AM EDT - 4 weeks ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Sep 5, 2025, 6:05 PM EDT - 7 weeks ago

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Sep 3, 2025, 7:00 AM EDT - 7 weeks ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 12, 2025, 8:00 PM EDT - 2 months ago

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 2 months ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 2 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 2 months ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 2 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 3 months ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 4 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 4 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 5 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 5 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 5 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 5 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 5 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 6 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 8 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 8 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 8 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 9 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 11 months ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 11 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 11 months ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 1 year ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 1 year ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Jun 23, 2024, 1:30 PM EDT - 1 year ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's

theThroatSlasher Oct. 24 at 11:12 AM

$NEUP management is buying its own stock to prevent it from sliding off the damned edge into a precipice and joining goofs such as $GUTS back on Aug 6

0 · Reply

speculator Oct. 23 at 11:27 AM

0 · Reply

Mr_Pean Oct. 23 at 11:09 AM

$GUTS no need for maintenance GLP-1 shots for life! Revita addresses the root cause of obesity with a an outpatient procedure to provide durable weight maintenance for patients living with obesity!

0 · Reply

BioRich Oct. 23 at 3:08 AM

0 · Reply

Fede_Tech Oct. 21 at 11:24 AM

$GUTS Current value: $1.39 MA200: $1.49 If it breaks, it will explode. Simple as that.

0 · Reply

Mr_Pean Oct. 21 at 5:56 AM

$GUTS my kind of day!

0 · Reply

Fede_Tech Oct. 20 at 9:33 PM

$GUTS 6,412,201 shares held by Peter Thiel, which looks like it has found bottom.

0 · Reply

tmpl Oct. 20 at 7:58 PM

$GUTS It is almost there

0 · Reply

BioRich Oct. 17 at 7:57 PM

1 · Reply

Mr_Pean Oct. 15 at 11:56 PM

$GUTS was hoping for more out of today.

2 · Reply

BioRich Oct. 15 at 9:12 PM

$XBI Looks like yesterday's picks turned out pretty well, led by $SBFM. I see that continuing to run as it gets more attention. Could be a multi-bagger. Also, 1) $GUTS My #1 "Must Have" Bio. You thought Wegovy was a big deal, check out his beauty. Retains weight loss when you discontinue a GLP-1 and also has shown insane weight loss in early models using gene therapy (not their lead, but very exciting). Will be subject of massive BO/PS. 2) $IVA If you're interested in the MASH/Fibrosis/Liver space (which is increasingly becoming as popular as Obesity), this is your pick. P3 with impressive Fibrosis Improvement data. Expect them to get BO too. 3) Added more $GDRX. This was a great pick at these levels before the TrumpRX news. Still a great pick and will go parabolic if TrumpRx takes off and uses GDRX (No political posts, please). Follow/Subscribe for more suggestions/perspective. Would love to hear yours too. Let's make some money. Cheers!

1 · Reply

BioRich Oct. 15 at 8:52 PM

$ALT Friendly reminder for those looking towards this ticker for the next big thing...RUN! The Bulls on this page spread misinformation and act like Uncle Rico about what could have been. They won't tell you the truth, but this company failed their trial, they have discontinued countless programs, they withhold data (while diluting) and are facing intense legal and securities fraud attention. Simple test...if it did 1/3 of what this board pumps "it does", this would be trading at $20/share. It's not, and for good reason. If you want in the MASH/fibrosis race, get some $IVA. If you want in the Obesity sector, invest as heavily as you possibly can in $GUTS. $VERU is an interesting one and $TERN continues to soar on the cusp on transformational data. Follow/Subscribe for more suggestions and pespective. Would love to hear yours too. That's how we find these gems (not ALT) and learn. Let's make some money. Cheers!

0 · Reply

Mr_Pean Oct. 14 at 4:49 AM

$GUTS I have been given advice that this is one of the best places to park your money. Double

0 · Reply

BioRich Oct. 13 at 4:45 PM

$GUTS Nice entry point here. Could still drift towards $1.25 if we have a few market down days, but I'm comfortable with where we're at. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

0 · Reply

Mr_Pean Oct. 11 at 12:10 AM

$GUTS not a great week but I’m optimistic about next week.

0 · Reply

MilsLearning Oct. 10 at 5:42 PM

$GUTS Ever get bullied??? Trading stocks?? Me too!!! Well 🩳🔥🖕🔥🩳🔥🖕🔥🩳🖕

0 · Reply

Mr_Pean Oct. 10 at 4:35 AM

$GUTS was hoping for more out of today.

0 · Reply

_CircuitBreaker Oct. 9 at 11:53 PM

Keep a close watch on CMCT! $OFAL $CAMP $GUTS $MNMD /

0 · Reply

BioRich Oct. 9 at 9:34 PM

$XBI I believe the Super Deal that can happen, that will give BP a giant killer, would be someone going after $IVA $GUTS and $VERU. I think that deal could come in between $6-8B, with $100B total market share return potential. These numbers may be low, but I believe their realistic. Here's how I see it: $IVA - Fibrosis Improvement with other cardio-metabolic benefits. $GUTS - Weight Loss Retention following GLP-1 discontinuation + Gene Therapy for WL. $VERU - Lean Mass Preservation in combination of GLP-1. Obviously, no one called me, but looking at a Dream Team, I think this gets the job done. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

0 · Reply

StockTraderDrew Oct. 9 at 7:23 PM

$GUTS still bullish in short/medium term. might take a few weeks to cook tho.

0 · Reply

Mr_Pean Oct. 8 at 11:43 PM

$GUTS I’ll take it.

0 · Reply

BanCrupt Oct. 8 at 9:40 AM

$GUTS data release is not so impressive, which is probably why stock is down. relative to placebo, diet-induced obese mice lost 29% body weight from baseline in 35 days with RJVA-002. $VKTX's preclinical mouse model showed 28.4% reduction for VK2735 and 29.22% for Tirzepatide in 14 days. poster here https://vikingtherapeutics.com/wp-content/uploads/Yagiz_Novel-dual-incretin-receptor-agonists_Poster-207_20Oct2021-1.pdf see fig and tab 1. So RJVA-002 is not competitive in preclinical data at all. But it is a gene therapy, which is a unique MoA, so there is likely to be some value to it, probably for harder to treat patients with diabetes. remains to be seen how it performs in clinical trials with humans, which start in 2026. neither bearish nor bullish on this data, but it's not "good" data in context of existing or soon-to-market obesity treatments.

0 · Reply

Market Cap	69.40M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	-1.65

Volume	908,900
Avg Vol	3,456,170
Day's Range	N/A - N/A
Shares Out	50.29M
Stochastic %K	82%
Beta	2.27
Analysts	Strong Sell
Price Target	$6.76